Pertuzumab and Trastuzumab Emtansine for Human Epidermal Growth Factor Receptor-2–Positive Metastatic Breast Cancer: Contemporary Population-Based Outcomes

Background: Real-world outcomes for patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer (MBC) treated with pertuzumab in combination with taxane chemotherapy plus trastuzumab (TaxTP) in the first line setting and trastuzumab emtansine (TE) in any line of t...

Full description

Bibliographic Details
Main Authors: Sasha Lupichuk, Winson Y Cheung, Douglas Stewart
Format: Article
Language:English
Published: SAGE Publishing 2019-10-01
Series:Breast Cancer: Basic and Clinical Research
Online Access:https://doi.org/10.1177/1178223419879429